0.0025
-0.0002
(-7.41%)
Delayed:
12:23PM EDT
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 0.00 - 0.00 |
| 52 week | 0.00 - 0.03 |
| Open | 0.00 |
| Vol / Avg. | 3.13M/7.16M |
| Mkt cap | 1.12M |
| P/E | - |
| Div/yield | - |
| EPS | -0.05 |
| Shares | 446.52M |
| Beta | 41.93 |
| Inst. own | 0% |
Key stats and ratios
| Q3 (Aug '12) | 2012 | |
| Net profit margin | -380.64% | -443.30% |
| Operating margin | -205.53% | -356.15% |
| EBITD margin | - | -189.30% |
| Return on average assets | -327.61% | -348.69% |
| Return on average equity | - | -10759.85% |
| Employees | 10 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 304, 4700 Spring Street
LA MESA, CA 91942
United States - Map
+1-619-7021404 (Phone)
+1-619-3302328 (Fax)
LA MESA, CA 91942
United States - Map
+1-619-7021404 (Phone)
+1-619-3302328 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Entest BioMedical, Inc. (Entest) is a development-stage company. During the fiscal year ended August 31, 2012, the Company�s business consists of the development and commercialization of immunotherapeutic therapies for the veterinary market, as well as the acquisition and operation of veterinary hospitals. The Company is focusing its research and development efforts toward the development and commercialization of the ImenVax family of canine cancer vaccines. ImenVax I is a therapeutic for canine cancer, which involves isolating tumor cells from the patient and then placing the cells into a cell implant device that is inserted subcutaneously into the patient. ImenVax II, which utilizes cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses.
Officers and directors
| David R. Koos M.D. | Chairman of the Board, President, Chief Executive Officer, Acting Chief Financial Officer, Principal Accounting Officer, Secretary |